Cancer represents a significant global health and economic burden due to its high mortality
rates. While effective in some instances, traditional chemotherapy often falls short of entirely …

The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains
poor, with a median survival of 2–4 years. About 10% of newly diagnosed breast cancer …

Over 15 years ago, low-dose metronomic chemotherapy was shown to induce disease
control in patients with advanced-stage breast cancer with a lower incidence of adverse …

Introduction Metronomic chemotherapy (mCHT) is a treatment regimen in which drugs are
administered frequently or continuously and that maintains low, prolonged, and …

Metronomic chemotherapy (mCHT), defined as continuous administration of low-dose
chemotherapeutic agents with no or short regular treatment-free intervals, was first …

Abstract Background: Metronomic chemotherapy (MCT), termed sustained low-dose
administration with minimal toxicity, is a new modality of conventional chemotherapy, a …

Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic
drug for a long time with no extended drug-free breaks. It was developed to overcome drug …

Metronomic chemotherapy has arrived. In 2014 we are beginning to learn of phase III
clinical trial results on this form of cancer treatment, defined by the continuous low-dose …

Metronomic administration of chemotherapy has long been recognized as having a different
biological effect from maximal tolerated dose (MTD) administration. Preclinical studies have …

Tumor angiogenesis is recognized as a major therapeutic target in the fight against cancer.
The key involvement of angiogenesis in tumor growth and metastasis has started to redefine …